- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03419312
PET Patterns, Biomarkers and Outcome in Burst SCS Treated FBSS Patients (PET-SCS)
Cerebral PET Patterns, Inflammatory Biomarkers and Outcome in Patients Treated With Burst Spinal Cord Stimulation for Chronic Low Back and Leg Pain: A Randomized Controlled Clinical Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Background and rationale:
Tonic spinal cord stimulation for chronic primarily neuropathic pain har been used for over 50 years. Tonic stimulation in frequencies from 20 to 70 Hz produces analgesia and paresthesia in the targeted area.
Burst stimulation, a novel spinal cord stimulation pattern, is an intermittent high frequency parenthesis-free therapy. This stimulation pattern consist of 5 spikes with an inter-spike frequency of 500 Hz, delivered at 40 Hz.
Clinical effectiveness and noninferiority of Burst stimulation has been proved. A few studies suggest that Burst stimulation induce different activities in cerebral pathways, compared with tonic stimulation. Patient reported attention to pain assessed by the pain vigilance and awareness questionnaire (PVAQ) seems to differ between burst and tonic spinal cord stimulation. This trial is designed to investigate cerebral mechanisms of burst stimulation, using PET O15-water measured blood flow and tissue perfusion as a proxy for cerebral activity.
Key events in study implementation:
Study phase 1
- Study Inclusion and baseline visit.
- Implantation of spinal cord stimulation system.
Study phase 2:
- Study visit 1(study day 0): Collection of Patient Reported Outcome Measurements (PROM) data, Randomization to study sequence, blood sampling, PET 0, programming of SCS-system.
- Study visit 2 (study day 14): Blood sampling, PET 1, collection of PROM-data, SCS system switched off for washout.
- Study visit 3 (study day 21): Collection of PROM-data, programming of SCS-system, blood sampling.
- Study visit 4 (study day 35): Blood sampling, PET 2, collection of PROM-data, programming of SCS-system.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden, 75185
- Uppsala University Hospital, Uppsala University, Dept. of Surgical Sciences and Dept. of Medicinal Chemistry, Div. of Molecular Imaging.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Occurrence of chronic pain in the lumbosacral region, as well as unilateral or bilateral leg pain.
- Prior lumbar surgery in medical history.
- Diagnosed with neuropathic pain in the lower extremities and graded as probable neuropathic pain or definite neuropathic pain according International Association for the Study of Pain (IASP) criteria.
- Patient report largely unchanged pain condition last 6 months.
Patient has undergone a 7 day SCS trial with epidural burst stimulation with the following results:
- At least 75% coverage of the painful area of tonic stimulation before start of burst trial stimulation.
- At least 50% reduction in pain intensity, measured via BPI, item 5 from baseline of trial to end of trial period.
- The patient is ≥ 18 years of age and < 60 years of age.
- The patient must willingly participate in all parts of the study, as well as having the ability to complete the entire study plan.
- Patient must certify that he / she understands the study plan, as well as voluntarily sign informed consent to participate in the study.
- Must be able to sit still for a minimum of 45 minutes and be able to follow restrictions related to the PET survey.
Exclusion Criteria:
- The patient has other current pain conditions than back and leg pain after back surgery.
- The patient is treated with opioids exceeding 80 milligrams of Morphine per day or is considered at risk for development of problematic opioid use.
- The patient suffers from an untreated depression or anxiety.
- The patient can not complete the study plan.
- The patient is unable to read or write Swedish.
- The patient is currently participates in another clinical trial.
- A history of previous PET scan or other substantial radiation dose in the last 5 years.
- The patients is suffering from claustrophobia.
- Ongoing pregnancy or planned pregnancy during study time.
- The patient has contraindications for arterial catheterization.
- The patient is previously treated with spinal cord stimulation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study sequence A
Proclaim™ Elite 5: Burst - Washout - Sham
|
All implanted hardware manufactured by S:t Jude Medical/Abbot: Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106.
Other Names:
|
Experimental: Study sequence B
Proclaim™ Elite 5: Sham - Washout - Burst
|
All implanted hardware manufactured by S:t Jude Medical/Abbot: Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in regional cerebral blood flow measured with 15O-water Positron Emission. Tomography (PET)
Time Frame: PET is performed at study day 0 (baseline), day 14 and day 35.
|
35 Volume of Interest (VOI) will be applied to each PET scan using the PVElab software.
Cerebral blood flow (CBF) and perfusable tissue fraction (PTF) will be calculated for each VOI at each scan.
Same tests will be done at voxel level with the Statistical Parameter Mapping Software (SPM12), to identify areas with changed CBF or PTF that do not correspond to VOI in the template.
|
PET is performed at study day 0 (baseline), day 14 and day 35.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Semiquantitative assessment of protein levels associated with inflammation.
Time Frame: Measured at day 0 (baseline), day 14, day 21 and day 35.
|
Level of normalized protein expression (NPX) in plasma, assessed by a multiplex proximity extension assay panel (Olink Bioscience, Uppsala, Sweden).
|
Measured at day 0 (baseline), day 14, day 21 and day 35.
|
Back and leg pain
Time Frame: Measured at visit day 0 (baseline), day 14 and day 35.
|
Measured using a 100mm Visual Analog Scale (VAS) for back and leg pain, respectively.
Scale range: 0 mm indicates no pain (minimum), 100 mm indicates worst imaginable pain (maximum).
|
Measured at visit day 0 (baseline), day 14 and day 35.
|
General pain
Time Frame: Measured at day 0 (baseline), day 14 and day 35.
|
General pain measured by Brief Pain Inventory (BPI) item 3, 4, 5 and 6
|
Measured at day 0 (baseline), day 14 and day 35.
|
Pain inference
Time Frame: Measured at day 0 (baseline), day 14 and day 35.
|
Measured by BPI item 9A-9G
|
Measured at day 0 (baseline), day 14 and day 35.
|
Disability
Time Frame: Measured at day 0 (baseline), day 14 and day 35.
|
Disability measured by Oswestry Disability Index (ODI).
|
Measured at day 0 (baseline), day 14 and day 35.
|
Pain Catastrophizing
Time Frame: Measured at day 0 (baseline), day 14 and day 35.
|
Measured by Pain Catastrophizing Scale (PCS).
|
Measured at day 0 (baseline), day 14 and day 35.
|
Pain Vigilance and Awareness
Time Frame: Measured at day 0 (baseline), day 14 and day 35.
|
Measured by the Pain Vigilance and Awareness Questionnaire (PVAQ).
|
Measured at day 0 (baseline), day 14 and day 35.
|
Global Impression of Change
Time Frame: Measured at day 14 and day 35.
|
Impression of change in health status assessed by the inventory Patient Global Impression of Change (PGIC).
|
Measured at day 14 and day 35.
|
Depression
Time Frame: Measured at day 0 (baseline), day 14 and day 35.
|
Symptoms of depression is assessed by the inventory Patient Health Questionnaire (PHQ-9).
|
Measured at day 0 (baseline), day 14 and day 35.
|
Anxiety
Time Frame: Measured at day 0 (baseline), day 14 and day 35.
|
Symptoms of anxiety is assessed by the inventory Generalized Anxiety Disorder Screener (GAD-7).
|
Measured at day 0 (baseline), day 14 and day 35.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rolf Karlsten, MD, PhD, rolf.karlsten@akademiska.se
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB 2017/110/1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Back Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
University School of Physical Education in WroclawCompletedLow Back Pain | Low Back Pain, Mechanical | Low Back Pain, PosturalPoland
-
Texas Woman's UniversityTexas Physical Therapy AssociationCompletedLow Back Pain | Chronic Low Back Pain | Subacute Low Back PainUnited States
-
University of ParmaKing's College London; Helmholtz Zentrum München; GENOS; Ip Research Consulting... and other collaboratorsUnknownChronic Low Back Pain | Acute Low Back PainUnited States, Australia, Belgium, Croatia, Italy, United Kingdom
-
Ache Laboratorios Farmaceuticos S.A.Unknown
-
Palmer College of ChiropracticDepartment of Health and Human ServicesCompletedChronic Low Back Pain | Subacute Low Back PainUnited States
-
Universität Duisburg-EssenSiemens-BetriebskrankenkasseCompletedChronic Low Back Pain | Recurrent Low Back Pain
-
Karolinska InstitutetCompletedChronic Low Back Pain | Recurrent Low Back Pain | Persistent Low Back PainSweden
-
Apsen Farmaceutica S.A.CompletedLow Back Pain | Low Back Pain, Mechanical | Acute Low Back PainBrazil